Article Information
History
- February 20, 2020.
Article Versions
- Version 1 (January 10, 2020 - 06:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Vanteemar S Sreeraj, DPM, DNB (Psychiatry), PDF (Clinical Neurosciences and therapeutics in Schizophrenia),
- Bharath Holla, MD, PDF (Addiction Psychaitry),
- Dhruva Ithal, MD,
- Ravi Kumar Nadella, MD,
- Jayant Mahadevan, MD, DM (Addiction Psychiatry),
- Srinivas Balachander, MD, PDF (OCD),
- Furkhan Ali, MD,
- Sweta Sheth, MD,
- Janardhanan C. Narayanaswamy, MD,
- Ganesan Venkatasubramanian, MD, PhD,
- John P. John, MD,
- Mathew Varghese, MD,
- Vivek Benegal, MD, DPM,
- Sanjeev Jain, MD,
- YC Janardhan Reddy, MD,
- ADBS Consortium and
- Biju Viswanath, MD, PhD.*
- Department of Psychiatry, National Institute of Mental health and Neurosciences (NIMHANS), Bengaluru, India
- ↵*Corresponding Author:
Dr. Biju Viswanath, Associate Professor of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India 560029, Phone: +91 80 2699 5791; Mob: +919480829594, Email: bijuv1{at}gmail.com